DeveloGen, BI Partner in €244M Diabetes Pact
BioWorld International Correspondent
DeveloGen AG is getting an up-front payment of €7 million (US$9.52 million) and could earn as much as €237 million more in milestone payments from Boehringer Ingelheim GmbH, in return for a novel drug target for Type II diabetes and other metabolic diseases, a series of chemical leads and associated intellectual property and know-how.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST